



NOTICE OF 5TH ANNUAL GENERAL MEETING

NOTICE is hereby given that 5th Annual General Meeting of the Members of Gujarat Kidney And Super Speciality Limited (formerly known as Gujarat Kidney and Super Speciality Private Limited and Vihaan Medicare Private Limited) will be held at 11:00 a.m.(IST) on Monday, 30th September, 2024 at the registered office at Plot no.1, City Survey no. 1537/A, Jetalpur Road, Gokak Mill Compound, Alkapuri, Vadodara-390020 (Gujarat) at shorter notice to transact the following special business:

ITEM NO. 1 ADOPTION OF FINANCIAL STATEMENTS FOR THE YEAR ENDED 31st MARCH 2024.

ITEM NO. 2 TO CONSIDER AND APPROVE APPOINTMENT OF SHRI PRAGNESH BHARPODA (DIN - 01033141) AS A DIRECTOR OF THE COMPANY, WHO RETIRES BY ROTATION AND BEING ELIGIBLE OFFERS HIMSELF FOR RE-APPOINTMENT

ITEM NO. 3 APPOINTMENT OF M/s. Y M SHAH & CO AS STATUTORY AUDITOR OF THE COMPANY TO FILL CASUAL VACANCY

To consider and if thought fit, to pass following resolution with or without modification(s) as
Ordinary Resolution

“RESOLVED THAT pursuant to the provisions of Section 139, 142 and other applicable provisions, if any of the Companies Act, 2013 read with the Companies (Audit and Auditors) Rules, 2014 (including any statutory modification(s) or re-enactment(s) thereof for the time being in force) and pursuant to the recommendation of the Board, M/s. Y M SHAH & CO Chartered Accountants, Mumbai (FRN: 114124W) be and is hereby appointed as the Statutory Auditors of the Company, to hold office for a period of 5 (five) consecutive years commencing from the conclusion of this Annual General Meeting till the conclusion of the 10th Annual General Meeting of the Company to be held in the financial year 2028-29, at such remuneration as may be determined by the Board in consultation with the auditors in addition to reimbursement of all out-of-pocket expenses to be incurred by them in connection with the audit.”

Gujarat Kidney And Superspeciality Limited

Formerly known as Gujarat Kidney And Superspeciality Private Limited / Previously known as Vihaan Medicare Private Limited
CIN : U85300GJ2019PLC111559

Reg. Office : Plot No.1, City Survey No 1537/A, Gokak Mill Compound, Jetalpur Road, Alkapuri,
Vadodara - 390020, Gujarat, India. E-mail : gujaratkidneyhospital1@gmail.com / www.gujaratsuperspecialityhospital.com

For Appointment Please Dial ☎ 0265 - 2984 800 / +91 96870 79991



**ITEM NO 4. APPOINTMENT OF M/s. Y M SHAH & CO AS STATUTORY AUDITOR OF THE
COMPANY FOR A PERIOD OF 5 YEARS**

To consider and if thought fit, to pass following resolution with or without modification(s) as
Ordinary Resolution

“**RESOLVED THAT** pursuant to the provisions of Section 139, 142 and other applicable provisions, if any of the Companies Act, 2013 read with the Companies (Audit and Auditors) Rules, 2014 (including any statutory modification(s) or re-enactment(s) thereof for the time being in force) and pursuant to the recommendation of the Board, M/s. Y M SHAH & CO Chartered Accountants, Mumbai (FRN: 114124W) be and is hereby appointed as the Statutory Auditors of the Company, to hold office for a period of 5 (five) consecutive years commencing from the conclusion of this Annual General Meeting till the conclusion of the 10th Annual General Meeting of the Company to be held in the financial year 2028-29, at such remuneration as may be determined by the Board in consultation with the auditors in addition to reimbursement of all outof-pocket expenses to be incurred by them in connection with the audit.”

By the order of the Board
**Gujarat Kidney And Super Speciality
Limited**

Date:- 15thSeptember,2024
Place:-Vadodara



Pragnesh Yashwantsinh Bharpoda
Director
(DIN:-01033141)

Gujarat Kidney And Superspeciality Limited

Formerly known as Gujarat Kidney And Superspeciality Private Limited / Previously known as Vihaan Medicare Private Limited
CIN : U85300GJ2019PLC111559

Reg. Office : Plot No.1, City Survey No 1537/A, Gokak Mill Compound, Jetalpur Road, Alkapuri,
Vadodara - 390020, Gujarat, India. E-mail : gujaratkidneyhospital1@gmail.com / www.gujaratsuperspecialityhospital.com

For Appointment Please Dial ☎ 0265 - 2984 800 / +91 96870 79991



**EXPLANATORY STATEMENT PURSUANT TO SECTION 102 OF THE
COMPANIES ACT, 2013**
For Item no 3 & 4

M/s. Khambhat & Co, LLP (firm registration number 001609S/S000162) have tendered their resignation as Statutory Auditors w.e.f. 30th August 2024 because of not devoting proper time due prior commitment to existing client. This has resulted into a casual vacancy in the office of Statutory Auditors of the Company as envisaged by Section 139(8) of the Companies Act, 2013. M/s. Khambhat & Co, LLP has completed the Statutory Audit for the Financial Year 2023-24 and issued Independent Audit Report on 27th August, 2024. However, due to reasons as stated above, they have resigned from the position of Statutory Auditor of the Company.

The Board of Directors of the Company at its Board Meeting held on 15th September, 2024 recommend to appoint M/s. Y M Shah & Co, Chartered Accountants (FRN 114124W) as Statutory Auditors of the Company to fill the casual vacancy caused due to resignation of M/s. M/s. Khambhat & Co, LLP. Casual vacancy caused by the resignation of Statutory Auditors are required to be approved by the shareholders in General Meeting within three months from the date of recommendation of the Board of Directors of the Company.

Considering the provisions of Section 139(8) of the Companies Act, 2013, any vacancy caused due to resignation of Statutory Auditors are required to be approved by the Shareholders at a General Meeting convened within 3 months of the recommendation of the Board and he shall hold the office till the conclusion of the next Annual General Meeting. Since the upcoming General Meeting is this Annual General Meeting and hence, the Board recommend to appoint him for a period of 5 years from the conclusion of this ensuing Annual General Meeting to conclusion of 10th Annual General Meeting.

M/s. Y M Shah & Co, Chartered Accountants have conveyed their consent for being appointed as the Statutory Auditors of the Company along with a confirmation that, their appointment, if made by the members, would be within the limits prescribed under the Companies Act, 2013 and shall satisfy the criteria as provided under section 141 of the Companies Act, 2013..

The Board of Directors of the Company recommends to pass the resolution of Item No. 2 & 3 of the notice as ordinary resolution

None of the Directors or Key Managerial Persons of the Company (including their relatives), except to the extent of their shareholding in the Company, are concerned or interested in the said resolution.

NOTES :

1. A member is entitled to attend and vote is entitled to appoint a proxy to appoint proxy to attend and vote instead of himself/herself and the proxy need not to be a member.

Gujarat Kidney And Superspeciality Limited

Formerly known as Gujarat Kidney And Superspeciality Private Limited / Previously known as Vihaan Medicare Private Limited
CIN : U85300GJ2019PLC111559

Reg. Office : Plot No.1, City Survey No 1537/A, Gokak Mill Compound, Jetalpur Road, Alkapuri,
Vadodara - 390020, Gujarat, India. E-mail : gujaratkidneyhospital1@gmail.com / www.gujaratsuperspecialityhospital.com

For Appointment Please Dial ☎ 0265 - 2984 800 / +91 96870 79991



2. Pursuant to section 105(1) of the Companies Act, 2013, read with rule 19 of the companies (Management and Administration Rules), 2014, aperson can act as proxy on behalf of member not exceeding 50 (fifty) in number and holding in aggregate not more than 10 (ten) percent of the total share capital of the company carrying voting rights. In case member holding more than 10(ten) percent of the total share capital of the company carrying voting rights, such a member may appoint a single person as proxy, who however shall not act as proxy for any other person or shareholder.
3. Proxies in order to be effective must be lodged form MGT-11 with the company not less than 48 hours before the commencement of meeting.
4. Corporate Members intending to send their authorized representative(s) pursuant to section 113 of the Companies Act, 2013 to attend the Meeting are requested to send a certified copy of the Board Resolution authorizing their representative to attend and vote on their behalf at the Meeting. A person authorised by resolution under Section 113(1) of the Companies Act, 2013, shall be entitled to exercise the same rights and powers, including the right to vote by proxy, on behalf of the body corporate which he/she represents.
5. The relevant Explanatory statement in respect of above businessesare annexed hereto.
6. Statutory registers as required under the provisions of the Act will be made available for inspection by the members at the EGM venue during the continuance of the meeting.
7. Route Map of the venue of the Extraordinary General Meeting forms part of this notice.
8. Members / proxies / authorized representatives should bring the duly filled Attendance Slip enclosed herewith to attend the meeting.



Date:- 15thSeptember,2024
Place:-Vadodara

By the order of the Board
Gujarat Kidney And Super Speciality
Limited

Pragnesh Yashwantsinh Bharpoda
Director
(DIN:-01033141)

Gujarat Kidney And Superspeciality Limited

Formerly known as Gujarat Kidney And Superspeciality Private Limited / Previously known as Vihaan Medicare Private Limited
CIN : U85300GJ2019PLC111559

Reg. Office : Plot No.1, City Survey No 1537/A, Gokak Mill Compound, Jetalpur Road, Alkapuri,
Vadodara - 390020, Gujarat, India. E-mail : gujaratkidneyhospital1@gmail.com / www.gujaratsuperspecialityhospital.com

For Appointment Please Dial 0265 - 2984 800 / +91 96870 79991



**BOARD REPORT FOR PERIOD ENDED ON 31st MARCH, 2024
OF M/S. GUJARAT KIDNEY AND SUPER SPECIALITY LIMITED
(FORMERLY GUJARAT KIDNEY AND SUPER SPECIALITY PRIVATE LIMITED AND VIHAAN MEDICARE
PRIVATE LIMITED)**

To
The Members
Of M/s. GUJARAT KIDNEY AND SUPER SPECIALITY LIMITED
(FORMERLY GUJARAT KIDNEY AND SUPER SPECIALITY PRIVATE LIMITED
AND VIHAAN MEDICARE PRIVATE LIMITED)
Vadodara

Your Directors have pleasure in submitting their 5th Annual Report of the Company together with the Audited Statements of Accounts for the period ended 31st March, 2024.

1. FINANCIAL RESULTS

The Company's financial performance for the period under review figures is:

PARTICULARS	(Amount In Rupees in lakhs)	
	2023-24	2022-23
Net Sales /Income from Business Operations	497.97	00.00
Other Income	70.35	0.01
Total Income	568.31	0.01
Total Expense	374.06	0.63
Profit (Loss) Before Tax	194.25	(0.62)
Less Current Income Tax	53.88	00.00
Less Deferred Tax/ (Asset)	4.99	00.00
Net Profit (Loss) after Tax	145.36	(0.62)
Dividend (including Interim if any and final)	00.00	00.00
Net Profit after dividend and Tax	145.36	(0.62)
EPS (Basic and Diluted)	72.68	(0.31)

2. PERFORMANCE REVIEW AND STATE OF COMPANY'S AFFAIRS

During the Year under review, the Company has earned revenue from Operation of Rs. 497.97 lacs as compared to Nil revenue of previous Year. The Company has

Gujarat Kidney And Superspeciality Limited

Formerly known as Gujarat Kidney And Superspeciality Private Limited / Previously known as Vihaan Medicare Private Limited

CIN : U85300GJ2019PLC111559

Reg. Office : Plot No.1, City Survey No 1537/A, Gokak Mill Compound, Jetalpur Road, Alkapuri,

Vadodara - 390020, Gujarat, India. E-mail : gujaratkidneyhospital1@gmail.com / www.gujaratsuperspecialityhospital.com

For Appointment Please Dial ☎ 0265 - 2984 800 / +91 96870 79991

**BOARD REPORT FOR PERIOD ENDED ON 31st MARCH, 2024
OF M/S. GUJARAT KIDNEY AND SUPER SPECIALITY LIMITED
(FORMERLY GUJARAT KIDNEY AND SUPER SPECIALITY PRIVATE LIMITED AND VIHAAN MEDICARE
PRIVATE LIMITED)**

achieved net profit of Rs. 145.36 lacs as compared to loss of Rs.0.62 lacs of previous year.

3. DIVIDEND

During the period under review, the Board of Directors does not recommend any dividend. This is mainly due to conserve the Financial resources of the Company for the future growth of the Company.

4. AMOUNTS TRANSFERRED TO RESERVES

During the period under review the company has earned profit of Rs. 145.36 lacs and company transfer it's all the profit to Reserve and Surplus Account. As a result, the balance of Reserve and Surplus Account as on 31st March, 2024 is Rs.162.83 lacs.

5. MATERIAL CHANGES AND COMMITMENTS:

The Company has not made any material changes or commitments which affect the financial position of the Company between the end of the financial year to which the financial statements relate and the date of signing of this report.

6. SHARE CAPITAL AND CHANGE THEREIN

During the period under review, the Authorised Share Capital of the Company has been increased from Rs.25,00,000 to Rs.38,00,00,000 with the consent of members of the Company by way of Ordinary Resolution at Extra Ordinary General Meeting held on 6th September,2023.

During the period under review, there has been no change in the paid up share Capital of the Company. The Paid up share Capital of the Company as on 31st March,2024 was Rs.20,00,000.

a) Buy Back of Securities

Your Company has not bought back any of its securities during the year under review.

b) Sweat Equity



**BOARD REPORT FOR PERIOD ENDED ON 31st MARCH, 2024
OF M/S. GUJARAT KIDNEY AND SUPER SPECIALITY LIMITED
(FORMERLY GUJARAT KIDNEY AND SUPER SPECIALITY PRIVATE LIMITED AND VIHAAN MEDICARE
PRIVATE LIMITED)**

Your Company has not issued any Sweat Equity Shares during the year under review.

c) Bonus Shares

Your Company has not issued any Bonus Shares during the year under review.

d) Employee Stock Option Plan

Your Company has not provided any Stock Option Scheme to the employees.

7. CHANGE IN NATURE OF BUSINESS:

Your Company is engaged in the business of running multi speciality hospitals and there has been no change in the nature of business for the period under review.

CHANGE IN THE NAME OF THE COMPANY

During the period under review, the name of the Company has been changed from Vihaan Medicare Private Limited to Gujarat Kidney and Super Speciality Private Limited effective from 13th September, 2023.

CHANGE IN STATUS OF THE COMPANY (PRIVATE TO PUBLIC)

During the period under review, the status of the Company has been changed from Private Limited to Public Limited effective from 24th November, 2024.

8. DEPOSITS:

During the year under review, your Company has not accepted any deposits from public within the meaning of Section 73 of the Companies Act, 2013 ("the Act") read with Companies (Acceptance of Deposits) Rules, 2014. The Company has no unclaimed / unpaid matured deposit or interest due thereon.



BOARD REPORT FOR PERIOD ENDED ON 31st MARCH, 2024
OF M/S. GUJARAT KIDNEY AND SUPER SPECIALITY LIMITED
(FORMERLY GUJARAT KIDNEY AND SUPER SPECIALITY PRIVATE LIMITED AND VIHAAN MEDICARE
PRIVATE LIMITED)

9. DETAILS OF LOANS AVAILED FROM DIRECTORS OR THEIR RELATIVES:

As required under Clause (viii) of Rule 2 of Companies (Acceptance of Deposits) Rules, 2014, during the year under review the Company has availed loans from its Directors and/or from their relatives. Details of the same are as below

Sr.No	Name of Party	Nature of Relationship	Amount (Rs. in lacs)
1.	Yashwantsingh Bharpoda	Director	139.50
2.	Y M Bharpoda HUF	Relatives of Director	117.72

10. DETAILS OF SUBSIDIARY, JOINT VENTURE AND ASSOCIATE COMPANIES.

Your Company is not subsidiary Company of any holding Company as well as the Company does not have any Subsidiary, Associate or Joint Venture Company.

11. DETAILS OF DIRECTORS AND KEY MANAGERIAL PERSONNELS AND CHANGES THEREIN

As on 31st March, 2024, the Board of Directors of your Company comprised of 4 Directors. Details of the same are as follows

Sr.No	Name of Directors	DIN	Designation
1.	Anitaben Yashvantsinh Bharpoda	08644747	Director
2.	Bhartiben Pragnesh Bharpoda	08644746	Director
3.	Pragnesh Yashwantsinh Bharpoda	01033141	Director
4.	Yashwantsinh Bharpoda	08644745	Director

The Company has appointed Mrs. Veenus Gehlot as Company Secretary and Compliance Officer and Mrs. Bhavika Patel as Chief Financial Officer on 1st April, 2024.



**BOARD REPORT FOR PERIOD ENDED ON 31ST MARCH, 2024
OF M/S. GUJARAT KIDNEY AND SUPER SPECIALITY LIMITED
(FORMERLY GUJARAT KIDNEY AND SUPER SPECIALITY PRIVATE LIMITED AND VIHAAN MEDICARE
PRIVATE LIMITED)**

12. DIRECTORS RESPONSIBILITY STATEMENT

Pursuant to Section 134(3)(c) and 134(5) of the Companies Act, 2013, in relation to financial statements of the Company for the year ended 31 March 2024, the Board of Directors to the best of their knowledge and ability, confirm that:

- a) In the preparation of the annual accounts, the applicable accounting standards had been followed along with proper explanation relating to material departures;
- b) The directors had selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the company during the period and of the profit of the company for that period;
- c) The directors had taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of this Act for safeguarding the assets of the company and for preventing and detecting fraud and other irregularities;
- d) The directors had prepared the annual accounts on a going concern basis; and
- e) The directors had devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.

13. SIGNIFICANT / MATERIAL ORDER PASSED

During the year under review, no significant and material orders were passed by the regulators or courts or Tribunals impacting the going concern status and future operation of the Company.

14. CORPORATE SOCIAL RESPONSIBILITY

Considering the Net profit, Turnover and Net worth of the Previous Financial Year of the Company, the provisions of Section 135 of the Companies Act, 2013 with respect to Corporate Social Responsibility is not Applicable to the Company during the Financial year under review.



**BOARD REPORT FOR PERIOD ENDED ON 31ST MARCH, 2024
OF M/S. GUJARAT KIDNEY AND SUPER SPECIALITY LIMITED
(FORMERLY GUJARAT KIDNEY AND SUPER SPECIALITY PRIVATE LIMITED AND VIHAAN MEDICARE
PRIVATE LIMITED)**

15. NUMBER OF BOARD MEETINGS CONDUCTED DURING THE PERIOD UNDER REVIEW

Details of the Board meeting held during the financial year under review and attendance therein are as below

SN	Date of Meeting	No of Directors Entitled to attend the meeting	No of Directors Present
1.	10/04/2023	3	3
2.	20/06/2023	3	3
3.	12/08/2023	3	3
4.	04/09/2023	3	3
5.	25/09/2023	3	3
6.	02/11/2023	4	4
7.	18/02/2024	4	4
8.	22/02/2024	4	4
9.	15/03/2024	4	4

16. PARTICULARS OF EMPLOYEES

During the period under review, the Company was unlisted Company, hence the provision of Section 197(12) of the Companies Act, 2013 read with rules framed thereunder are not applicable to the Company.

17. STATUTORY AUDITORS

M/s. Kumbhat and Company, Chartered Accountants (Firm Registration No.0016095) were appointed as Statutory Auditors of the company in the casual vacancy caused due to resignation of M/s. Vipul Shah & Co. They will hold office till the ensuing Annual General Meeting.



**BOARD REPORT FOR PERIOD ENDED ON 31st MARCH, 2024
OF M/S. GUJARAT KIDNEY AND SUPER SPECIALITY LIMITED
(FORMERLY GUJARAT KIDNEY AND SUPER SPECIALITY PRIVATE LIMITED AND VIHAAN MEDICARE
PRIVATE LIMITED)**

18. EXPLANATION OR COMMENTS ON QUALIFICATIONS, RESERVATIONS OR ADVERSE REMARKS OR DISCLAIMERS MADE BY THE AUDITORS IN THEIR REPORTS:

There were no qualifications, reservations or adverse remarks made by the Statutory Auditors in their report. However, the Auditors has give one observation with respect to

Sr.No	Observation	Comments of the Board
1.	Based on our examination, which includes test check basis, the accounting software of the Company does not have a feature of recording audit trail (edit log) facility.	The Company has installed the software which has feature of Audit Trail (Edit log) facility in the Financial Year 2024-25.

The provisions with respect to the Secretarial Audit of the Company and to submission of Secretarial Audit Report are not applicable to the Company.

19. FRAUD REPORTING

During the period under review, the Statutory Auditors of the Company have not reported any fraud to the Board of Directors under Section 143 (12) of the Companies Act, 2013, and the rules made there under.

20. CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION, FOREIGN EARNING AND OUTGO

The particulars as required under the provisions of Section 134(3) (m) of the Companies Act, 2013 in respect of conservation of energy, technology Absorption, Foreign exchange earnings and outgo are as under

(A) Conservation of Energy

The operations of the Company are not energy intensive however, every effort is made to ensure optimum use of energy.

(i) the steps taken or impact on conservation of energy: Nil

(ii) the steps taken by the company for utilising alternate sources of energy: Nil

(iii) the capital investment on energy conservation equipments: Nil



**BOARD REPORT FOR PERIOD ENDED ON 31ST MARCH, 2024
OF M/S. GUJARAT KIDNEY AND SUPER SPECIALITY LIMITED
(FORMERLY GUJARAT KIDNEY AND SUPER SPECIALITY PRIVATE LIMITED AND VIHAAN MEDICARE
PRIVATE LIMITED)**

(B) Technology Absorption

(i) the efforts made towards technology absorption: Nil

(ii) the benefits derived like product improvement, cost reduction, product development or import substitution: Nil

(iii) in case of imported technology (imported during the last three years reckoned from the beginning of the financial year): Not Applicable

(iv) the expenditure incurred on Research and Development: Nil

(C) Foreign Exchange earnings and Outgo

During the year under, the Company has neither earned nor there is any outgo of Foreign Exchange.

21. PARTICULARS OF LOAN, GUARANTEE OR INVESTMENT MADE BY THE COMPANY

Your Company has not made any loans, Guarantee or investment during the year under review.

22. PARTICULARS OF CONTRACTS OR ARRANGEMENTS MADE WITH RELATED PARTIES

The Company has entered into related parties transactions as defined under Section 188 of the Companies Act, 2013 during the period under review. Details of the same are provided in the form AOC-2 attached at Annexure-A.

23. PREVENTION OF SEXUAL HARASSMENT OF WOMEN AT WORKPLACE:

Our Company always believed in providing a safe and harassment free workplace for every individual working in the Company premises. The Company has laid down policy on Prevention of Sexual Harassment at Workplace for identification, reporting and prevention of undesired behaviour on or by the Company employees or workforce.

During the year ended March 31, 2024, there were no complaints recorded pertaining to sexual harassment.



**BOARD REPORT FOR PERIOD ENDED ON 31st MARCH, 2024
OF M/S. GUJARAT KIDNEY AND SUPER SPECIALITY LIMITED
(FORMERLY GUJARAT KIDNEY AND SUPER SPECIALITY PRIVATE LIMITED AND VIHAAN MEDICARE
PRIVATE LIMITED)**

24. ANNUAL RETURN

Pursuant to Section 92(3) read with Section 134(3)(a) of the Companies Act, an Annual Return as on March 31, 2024 is required to be uploaded on the Company's website, if any.

Given the fact, that the Company has not any website, the Company has not uploaded the Annual Return on the website.

25. COMPLIANCE WITH SECRETARIAL STANDARD:

The Company has complied with the applicable Secretarial Standards, as issued by the Institute of Company Secretaries of India and approved by Central Government under Section 118(10) of the Companies Act, 2013.

26. PROCEEDINGS PENDING UNDER THE INSOLVENCY AND BANKRUPTCY CODE, 2016:

No application has been made or any proceeding is pending under the IBC, 2016.

27. INVESTOR EDUCATION AND PROTECTION FUND ("IEPF")

During the year under review, no amount is required to be transferred to Investors Education Protection Fund.

28. DIFFERENCE IN VALUATION:

Company has never made any one-time settlement against the loans obtained from Banks and Financial Institution and hence this clause is not applicable.

29. REVISION IN FINANCIAL STATEMENT OR BOARDS REPORT

During the year under review, no revision in Financial Statement or Boards Report has been made.



BOARD REPORT FOR PERIOD ENDED ON 31st MARCH, 2024
OF M/S. GUJARAT KIDNEY AND SUPER SPECIALITY LIMITED
(FORMERLY GUJARAT KIDNEY AND SUPER SPECIALITY PRIVATE LIMITED AND VIHAAN MEDICARE
PRIVATE LIMITED)

30. ACKNOWLEDGEMENTS

Your Directors place on record their sincere thanks to bankers, business associates, consultants, and various Government Authorities for their continued support extended to your Companies activities during the period under review. Your Directors also acknowledges gratefully the shareholders for their support and confidence reposed on your Company.

Date: 27th August, 2024

Place: Vadodara

FOR AND ON BEHALF OF THE BOARD OF DIRECTORS


PRAGNESH BHARPODA
DIRECTOR
(DIN: 01033141)




BHARTIBEN BHARPODA
DIRECTOR
(DIN:- 08644746)

**BOARD REPORT FOR PERIOD ENDED ON 31st MARCH, 2024
OF M/S. GUJARAT KIDNEY AND SUPER SPECIALITY LIMITED
(FORMERLY GUJARAT KIDNEY AND SUPER SPECIALITY PRIVATE LIMITED AND VIHAAN MEDICARE
PRIVATE LIMITED)**

**"ANNEXURE A"
FORM NO. AOC.2**

*(Pursuant to Clause (h) of Sub-Section (3) of Section 134 of the Act and
Rule 8(2) of the Companies (Accounts) Rules, 2014)*


1. Details of contracts or arrangements or transactions not at arm's length basis: - Not Applicable
2. Details of material contracts or arrangement or transactions at arm's length basis: -

Name(s) of the related party	Nature of Relationship	Nature of Contract	Duration of contract	Salient terms	Dates of Approval by the Board	Amount Rs. (in lacs)	Amount paid as advances, if any
Bhartiben Pragnesh Bharpoda	Director	Service	Continuous	--	10/04/2023	110.51	Nil
Anita Bharpoda	Director	Purchase	Continuous	--	10/04/2023	27.33	Nil
Pragnesh Bharpoda	Director	Business Transfer Agreement	NA	--	18/02/2024	906.37	
		Rent	Continuous	--	10/04/2023	2.12	

Date: 27th August, 2024

Place: Vadodara

FOR AND ON BEHALF OF THE BOARD OF DIRECTORS


PRAGNESH BHARPODA
DIRECTOR
(DIN: 01033141)


BHARTIBEN BHARPODA
DIRECTOR
(DIN:- 08644746)



BOARD REPORT FOR PERIOD ENDED ON 31st MARCH, 2024
OF M/S. GUJARAT KIDNEY AND SUPER SPECIALITY LIMITED
(FORMERLY GUJARAT KIDNEY AND SUPER SPECIALITY PRIVATE LIMITED AND VIHAAN MEDICARE
PRIVATE LIMITED)

"ANNEXURE A"
FORM NO. AOC.2

*(Pursuant to Clause (h) of Sub-Section (3) of Section 134 of the Act and
Rule 8(2) of the Companies (Accounts) Rules, 2014)*


1. Details of contracts or arrangements or transactions not at arm's length basis: - Not Applicable
2. Details of material contracts or arrangement or transactions at arm's length basis: -

Name(s) of the related party	Nature of Relationship	Nature of Contract	Duration of contract	Salient terms	Dates of Approval by the Board	Amount Rs. (in lacs)	Amount paid as advances, if any
Bhartiben Pragnesh Bharpoda	Director	Service	Continuous	--	10/04/2023	110.51	Nil
Anita Bharpoda	Director	Purchase	Continuous	--	10/04/2023	27.33	Nil
Pragnesh Bharpoda	Director	Business Transfer Agreement	NA	--	18/02/2024	906.37	
		Rent	Continuous	--	10/04/2023	2.12	

Date: 27th August, 2024

Place: Vadodara

FOR AND ON BEHALF OF THE BOARD OF DIRECTORS


PRAGNESH BHARPODA
DIRECTOR
(DIN: 01033141)


BHARTIBEN BHARPODA
DIRECTOR
(DIN:- 08644746)





**BOARD REPORT FOR PERIOD ENDED ON 31st MARCH, 2024
OF M/S. GUJARAT KIDNEY AND SUPER SPECIALITY LIMITED
(FORMERLY GUJARAT KIDNEY AND SUPER SPECIALITY PRIVATE LIMITED AND VIHAAN MEDICARE
PRIVATE LIMITED)**

To
The Members
Of M/s. GUJARAT KIDNEY AND SUPER SPECIALITY LIMITED
(FORMERLY GUJARAT KIDNEY AND SUPER SPECIALITY PRIVATE LIMITED
AND VIHAAN MEDICARE PRIVATE LIMITED)
Vadodara

Your Directors have pleasure in submitting their 5th Annual Report of the Company together with the Audited Statements of Accounts for the period ended 31st March, 2024.

1. FINANCIAL RESULTS

The Company's financial performance for the period under review figures is:

PARTICULARS	(Amount In Rupees in lakhs)	
	2023-24	2022-23
Net Sales /Income from Business Operations	497.97	00.00
Other Income	70.35	0.01
Total Income	568.31	0.01
Total Expense	374.06	0.63
Profit (Loss) Before Tax	194.25	(0.62)
Less Current Income Tax	53.88	00.00
Less Deferred Tax/ (Asset)	4.99	00.00
Net Profit (Loss) after Tax	145.36	(0.62)
Dividend (including Interim if any and final)	00.00	00.00
Net Profit after dividend and Tax	145.36	(0.62)
EPS (Basic and Diluted)	72.68	(0.31)

2. PERFORMANCE REVIEW AND STATE OF COMPANY'S AFFAIRS

During the Year under review, the Company has earned revenue from Operation of Rs. 497.97 lacs as compared to Nil revenue of previous Year. The Company has

Gujarat Kidney And Superspeciality Limited

Formerly known as Gujarat Kidney And Superspeciality Private Limited / Previously known as Vihaan Medicare Private Limited

CIN : U85300GJ2019PLC111559

Reg. Office : Plot No.1, City Survey No 1537/A, Gokak Mill Compound, Jetalpur Road, Alkapuri,

Vadodara - 390020, Gujarat, India. E-mail : gujaratkidneyhospital1@gmail.com / www.gujaratsuperspecialityhospital.com

For Appointment Please Dial ☎ 0265 - 2984 800 / +91 96870 79991

**BOARD REPORT FOR PERIOD ENDED ON 31st MARCH, 2024
OF M/S. GUJARAT KIDNEY AND SUPER SPECIALITY LIMITED
(FORMERLY GUJARAT KIDNEY AND SUPER SPECIALITY PRIVATE LIMITED AND VIHAAN MEDICARE
PRIVATE LIMITED)**

achieved net profit of Rs. 145.36 lacs as compared to loss of Rs.0.62 lacs of previous year.

3. DIVIDEND

During the period under review, the Board of Directors does not recommend any dividend. This is mainly due to conserve the Financial resources of the Company for the future growth of the Company.

4. AMOUNTS TRANSFERRED TO RESERVES

During the period under review the company has earned profit of Rs. 145.36 lacs and company transfer it's all the profit to Reserve and Surplus Account. As a result, the balance of Reserve and Surplus Account as on 31st March, 2024 is Rs.162.83 lacs.

5. MATERIAL CHANGES AND COMMITMENTS:

The Company has not made any material changes or commitments which affect the financial position of the Company between the end of the financial year to which the financial statements relate and the date of signing of this report.

6. SHARE CAPITAL AND CHANGE THEREIN

During the period under review, the Authorised Share Capital of the Company has been increased from Rs.25,00,000 to Rs.38,00,00,000 with the consent of members of the Company by way of Ordinary Resolution at Extra Ordinary General Meeting held on 6th September,2023.

During the period under review, there has been no change in the paid up share Capital of the Company. The Paid up share Capital of the Company as on 31st March,2024 was Rs.20,00,000.

a) Buy Back of Securities

Your Company has not bought back any of its securities during the year under review.

b) Sweat Equity



**BOARD REPORT FOR PERIOD ENDED ON 31st MARCH, 2024
OF M/S. GUJARAT KIDNEY AND SUPER SPECIALITY LIMITED
(FORMERLY GUJARAT KIDNEY AND SUPER SPECIALITY PRIVATE LIMITED AND VIHAAN MEDICARE
PRIVATE LIMITED)**

Your Company has not issued any Sweat Equity Shares during the year under review.

c) Bonus Shares

Your Company has not issued any Bonus Shares during the year under review.

d) Employee Stock Option Plan

Your Company has not provided any Stock Option Scheme to the employees.

7. CHANGE IN NATURE OF BUSINESS:

Your Company is engaged in the business of running multi speciality hospitals and there has been no change in the nature of business for the period under review.

CHANGE IN THE NAME OF THE COMPANY

During the period under review, the name of the Company has been changed from Vihaan Medicare Private Limited to Gujarat Kidney and Super Speciality Private Limited effective from 13th September, 2023.

CHANGE IN STATUS OF THE COMPANY (PRIVATE TO PUBLIC)

During the period under review, the status of the Company has been changed from Private Limited to Public Limited effective from 24th November, 2024.

8. DEPOSITS:

During the year under review, your Company has not accepted any deposits from public within the meaning of Section 73 of the Companies Act, 2013 ("the Act") read with Companies (Acceptance of Deposits) Rules, 2014. The Company has no unclaimed / unpaid matured deposit or interest due thereon.



BOARD REPORT FOR PERIOD ENDED ON 31st MARCH, 2024
OF M/S. GUJARAT KIDNEY AND SUPER SPECIALITY LIMITED
(FORMERLY GUJARAT KIDNEY AND SUPER SPECIALITY PRIVATE LIMITED AND VIHAAN MEDICARE PRIVATE LIMITED)

9. DETAILS OF LOANS AVAILED FROM DIRECTORS OR THEIR RELATIVES:

As required under Clause (viii) of Rule 2 of Companies (Acceptance of Deposits) Rules, 2014, during the year under review the Company has availed loans from its Directors and/or from their relatives. Details of the same are as below

Sr.No	Name of Party	Nature of Relationship	Amount (Rs. in lacs)
1.	Yashwantsingh Bharpoda	Director	139.50
2.	Y M Bharpoda HUF	Relatives of Director	117.72

10. DETAILS OF SUBSIDIARY, JOINT VENTURE AND ASSOCIATE COMPANIES.

Your Company is not subsidiary Company of any holding Company as well as the Company does not have any Subsidiary, Associate or Joint Venture Company.

11. DETAILS OF DIRECTORS AND KEY MANAGERIAL PERSONNELS AND CHANGES THEREIN

As on 31st March, 2024, the Board of Directors of your Company comprised of 4 Directors. Details of the same are as follows

Sr.No	Name of Directors	DIN	Designation
1.	Anitaben Yashvantsinh Bharpoda	08644747	Director
2.	Bhartiben Pragnesh Bharpoda	08644746	Director
3.	Pragnesh Yashwantsinh Bharpoda	01033141	Director
4.	Yashwantsinh Bharpoda	08644745	Director

The Company has appointed Mrs. Veenus Gehlot as Company Secretary and Compliance Officer and Mrs. Bhavika Patel as Chief Financial Officer on 1st April, 2024.



**BOARD REPORT FOR PERIOD ENDED ON 31ST MARCH, 2024
OF M/S. GUJARAT KIDNEY AND SUPER SPECIALITY LIMITED
(FORMERLY GUJARAT KIDNEY AND SUPER SPECIALITY PRIVATE LIMITED AND VIHAAN MEDICARE
PRIVATE LIMITED)**

12. DIRECTORS RESPONSIBILITY STATEMENT

Pursuant to Section 134(3)(c) and 134(5) of the Companies Act, 2013, in relation to financial statements of the Company for the year ended 31 March 2024, the Board of Directors to the best of their knowledge and ability, confirm that:

- a) In the preparation of the annual accounts, the applicable accounting standards had been followed along with proper explanation relating to material departures;
- b) The directors had selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the company during the period and of the profit of the company for that period;
- c) The directors had taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of this Act for safeguarding the assets of the company and for preventing and detecting fraud and other irregularities;
- d) The directors had prepared the annual accounts on a going concern basis; and
- e) The directors had devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.

13. SIGNIFICANT / MATERIAL ORDER PASSED

During the year under review, no significant and material orders were passed by the regulators or courts or Tribunals impacting the going concern status and future operation of the Company.

14. CORPORATE SOCIAL RESPONSIBILITY

Considering the Net profit, Turnover and Net worth of the Previous Financial Year of the Company, the provisions of Section 135 of the Companies Act, 2013 with respect to Corporate Social Responsibility is not Applicable to the Company during the Financial year under review.



**BOARD REPORT FOR PERIOD ENDED ON 31ST MARCH, 2024
OF M/S. GUJARAT KIDNEY AND SUPER SPECIALITY LIMITED
(FORMERLY GUJARAT KIDNEY AND SUPER SPECIALITY PRIVATE LIMITED AND VIHAAN MEDICARE
PRIVATE LIMITED)**

15. NUMBER OF BOARD MEETINGS CONDUCTED DURING THE PERIOD UNDER REVIEW

Details of the Board meeting held during the financial year under review and attendance therein are as below

SN	Date of Meeting	No of Directors Entitled to attend the meeting	No of Directors Present
1.	10/04/2023	3	3
2.	20/06/2023	3	3
3.	12/08/2023	3	3
4.	04/09/2023	3	3
5.	25/09/2023	3	3
6.	02/11/2023	4	4
7.	18/02/2024	4	4
8.	22/02/2024	4	4
9.	15/03/2024	4	4

16. PARTICULARS OF EMPLOYEES

During the period under review, the Company was unlisted Company, hence the provision of Section 197(12) of the Companies Act, 2013 read with rules framed thereunder are not applicable to the Company.

17. STATUTORY AUDITORS

M/s. Kumbhat and Company, Chartered Accountants (Firm Registration No.0016095) were appointed as Statutory Auditors of the company in the casual vacancy caused due to resignation of M/s. Vipul Shah & Co. They will hold office till the ensuing Annual General Meeting.



**BOARD REPORT FOR PERIOD ENDED ON 31st MARCH, 2024
OF M/S. GUJARAT KIDNEY AND SUPER SPECIALITY LIMITED
(FORMERLY GUJARAT KIDNEY AND SUPER SPECIALITY PRIVATE LIMITED AND VIHAAN MEDICARE
PRIVATE LIMITED)**

18. EXPLANATION OR COMMENTS ON QUALIFICATIONS, RESERVATIONS OR ADVERSE REMARKS OR DISCLAIMERS MADE BY THE AUDITORS IN THEIR REPORTS:

There were no qualifications, reservations or adverse remarks made by the Statutory Auditors in their report. However, the Auditors has give one observation with respect to

Sr.No	Observation	Comments of the Board
1.	Based on our examination, which includes test check basis, the accounting software of the Company does not have a feature of recording audit trail (edit log) facility.	The Company has installed the software which has feature of Audit Trail (Edit log) facility in the Financial Year 2024-25.

The provisions with respect to the Secretarial Audit of the Company and to submission of Secretarial Audit Report are not applicable to the Company.

19. FRAUD REPORTING

During the period under review, the Statutory Auditors of the Company have not reported any fraud to the Board of Directors under Section 143 (12) of the Companies Act, 2013, and the rules made there under.

20. CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION, FOREIGN EARNING AND OUTGO

The particulars as required under the provisions of Section 134(3) (m) of the Companies Act, 2013 in respect of conservation of energy, technology Absorption, Foreign exchange earnings and outgo are as under

(A) Conservation of Energy

The operations of the Company are not energy intensive however, every effort is made to ensure optimum use of energy.

(i) the steps taken or impact on conservation of energy: Nil

(ii) the steps taken by the company for utilising alternate sources of energy: Nil

(iii) the capital investment on energy conservation equipments: Nil



**BOARD REPORT FOR PERIOD ENDED ON 31ST MARCH, 2024
OF M/S. GUJARAT KIDNEY AND SUPER SPECIALITY LIMITED
(FORMERLY GUJARAT KIDNEY AND SUPER SPECIALITY PRIVATE LIMITED AND VIHAAN MEDICARE
PRIVATE LIMITED)**

(B) Technology Absorption

(i) the efforts made towards technology absorption: Nil

(ii) the benefits derived like product improvement, cost reduction, product development or import substitution: Nil

(iii) in case of imported technology (imported during the last three years reckoned from the beginning of the financial year): Not Applicable

(iv) the expenditure incurred on Research and Development: Nil

(C) Foreign Exchange earnings and Outgo

During the year under, the Company has neither earned nor there is any outgo of Foreign Exchange.

21. PARTICULARS OF LOAN, GUARANTEE OR INVESTMENT MADE BY THE COMPANY

Your Company has not made any loans, Guarantee or investment during the year under review.

22. PARTICULARS OF CONTRACTS OR ARRANGEMENTS MADE WITH RELATED PARTIES

The Company has entered into related parties transactions as defined under Section 188 of the Companies Act, 2013 during the period under review. Details of the same are provided in the form AOC-2 attached at Annexure-A.

23. PREVENTION OF SEXUAL HARASSMENT OF WOMEN AT WORKPLACE:

Our Company always believed in providing a safe and harassment free workplace for every individual working in the Company premises. The Company has laid down policy on Prevention of Sexual Harassment at Workplace for identification, reporting and prevention of undesired behaviour on or by the Company employees or workforce.

During the year ended March 31, 2024, there were no complaints recorded pertaining to sexual harassment.



**BOARD REPORT FOR PERIOD ENDED ON 31st MARCH, 2024
OF M/S. GUJARAT KIDNEY AND SUPER SPECIALITY LIMITED
(FORMERLY GUJARAT KIDNEY AND SUPER SPECIALITY PRIVATE LIMITED AND VIHAAN MEDICARE
PRIVATE LIMITED)**

24. ANNUAL RETURN

Pursuant to Section 92(3) read with Section 134(3)(a) of the Companies Act, an Annual Return as on March 31, 2024 is required to be uploaded on the Company's website, if any.

Given the fact, that the Company has not any website, the Company has not uploaded the Annual Return on the website.

25. COMPLIANCE WITH SECRETARIAL STANDARD:

The Company has complied with the applicable Secretarial Standards, as issued by the Institute of Company Secretaries of India and approved by Central Government under Section 118(10) of the Companies Act, 2013.

26. PROCEEDINGS PENDING UNDER THE INSOLVENCY AND BANKRUPTCY CODE, 2016:

No application has been made or any proceeding is pending under the IBC, 2016.

27. INVESTOR EDUCATION AND PROTECTION FUND ("IEPF")

During the year under review, no amount is required to transferred to Investors Education Protection Fund.

28. DIFFERENCE IN VALUATION:

Company has never made any one-time settlement against the loans obtained from Banks and Financial Institution and hence this clause is not applicable.

29. REVISION IN FINANCIAL STATEMENT OR BOARDS REPORT

During the year under review, no revision in Financial Statement or Boards Report has been made.



BOARD REPORT FOR PERIOD ENDED ON 31st MARCH, 2024
OF M/S. GUJARAT KIDNEY AND SUPER SPECIALITY LIMITED
(FORMERLY GUJARAT KIDNEY AND SUPER SPECIALITY PRIVATE LIMITED AND VIHAAN MEDICARE
PRIVATE LIMITED)

30. ACKNOWLEDGEMENTS

Your Directors place on record their sincere thanks to bankers, business associates, consultants, and various Government Authorities for their continued support extended to your Companies activities during the period under review. Your Directors also acknowledges gratefully the shareholders for their support and confidence reposed on your Company.

Date: 27th August, 2024

Place: Vadodara

FOR AND ON BEHALF OF THE BOARD OF DIRECTORS


PRAGNESH BHARPODA
DIRECTOR
(DIN: 01033141)




BHARTIBEN BHARPODA
DIRECTOR
(DIN:- 08644746)

**BOARD REPORT FOR PERIOD ENDED ON 31st MARCH, 2024
OF M/S. GUJARAT KIDNEY AND SUPER SPECIALITY LIMITED
(FORMERLY GUJARAT KIDNEY AND SUPER SPECIALITY PRIVATE LIMITED AND VIHAAN MEDICARE
PRIVATE LIMITED)**

**"ANNEXURE A"
FORM NO. AOC.2**

*(Pursuant to Clause (h) of Sub-Section (3) of Section 134 of the Act and
Rule 8(2) of the Companies (Accounts) Rules, 2014)*


1. Details of contracts or arrangements or transactions not at arm's length basis: - Not Applicable
2. Details of material contracts or arrangement or transactions at arm's length basis: -

Name(s) of the related party	Nature of Relationship	Nature of Contract	Duration of contract	Salient terms	Dates of Approval by the Board	Amount Rs. (in lacs)	Amount paid as advances, if any
Bhartiben Pragnesh Bharpoda	Director	Service	Continuous	--	10/04/2023	110.51	Nil
Anita Bharpoda	Director	Purchase	Continuous	--	10/04/2023	27.33	Nil
Pragnesh Bharpoda	Director	Business Transfer Agreement	NA	--	18/02/2024	906.37	
		Rent	Continuous	--	10/04/2023	2.12	

Date: 27th August, 2024

Place: Vadodara

FOR AND ON BEHALF OF THE BOARD OF DIRECTORS


PRAGNESH BHARPODA
DIRECTOR
(DIN: 01033141)


BHARTIBEN BHARPODA
DIRECTOR
(DIN:- 08644746)



INDEPENDENT AUDITORS' REPORT

**To the Members of
Gujarat Kidney and Superspeciality Limited**

Report on the Audit of the Financial Statements

Opinion

We have audited the accompanying financial statements of **Gujarat Kidney and Superspeciality Limited** ("the Company"), which comprise the Balance Sheet as at 31st March, 2024, the Statement of Profit and Loss and Cash Flow Statement for the year then ended and a summary of the significant accounting policies and other explanatory information.

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial statements give the information required by the Companies Act, 2013 in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at 31st March, 2024 and its profit and its cash flows for the year ended on that date.

Basis for opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the *Auditor's Responsibilities for the Audit of the Financial Statements* section of our report. We are independent of the Company in accordance with the *Code of Ethics* issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Companies Act, 2013 and the Rules there under, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Key Audit Matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the financial statements of the current period.



These matters were addressed in the context of our audit of the financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

We have determined that there are no key audit matters to communicate in our Report.

Information Other than the Financial Statements and Auditor's Report Thereon

The Company's Board of Directors is responsible for the other information. The other information comprises the information included in the Annual Report, but does not include the financial statements and our Auditor's Report thereon.

Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained during the course of our audit or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there is a material misstatement of this other information; we are required to Report that fact. We have nothing to Report in this regard.

Responsibility of Management and Those Charge with Governance for the Financial Statements

The Company's Board of Directors is responsible for the matters stated in section 134(5) of the Act with respect to the preparation of these financial statements that give a true and fair view of the financials position, financial performance, changes in equity and cash flows of the Company in accordance with the accounting principles generally accepted in India including the other accounting Standards specified under Section 133 of the Act. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities, selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.



In preparing the financial statements, the Board of Directors is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are responsible for overseeing the Company's financial Reporting process.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an Auditor's Report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal financial controls relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the Company has adequate internal financial controls system in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.



- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our Auditor's Report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our Auditor's Report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards. From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the financial statements of the current period and are therefore the key audit matters. We describe these matters in our Auditor's Report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our Report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Report on Other Legal and Regulatory Requirements

1. As required by the Companies (Auditor's Report) Order, 2020 ("the Order") issued by the Central Government of India in terms of Section 143(11) of the Act, we give in "Annexure A" a statement on the matters specified in paragraphs 3 and 4 of the Order.



Further to our comments in "Annexure A", as required by Section 143(3) of the Act, we Report that:

- a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purpose of our audit.
- b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books.
- c) The Balance Sheet, the Statement of Profit and Loss and the Statement of Cash Flow dealt with by this Report are in agreement with the relevant books of account.
- d) In our opinion, the aforesaid financial statements comply with the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014.
- e) On the basis of the written representations received from the directors as on March 31, 2024 taken on record by the Board of Directors, none of the directors is disqualified as on March 31, 2024 from being appointed as a director in terms of Section 164 (2) of the Act.
- f) With respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls, refer to our separate Report in "**Annexure B**". Our report expresses an unmodified opinion on the adequacy and operating effectiveness of the Company's internal financial controls with reference to standalone financial statements.
- g) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, as amended in our opinion and to the best of our information and according to the explanations given to us:
 - i. The Company does not have any pending litigations which would impact its financial position.
 - ii. The Company has not entered into any long term contracts including derivative contracts for which there were any material foreseeable losses, as required under the applicable law or Indian Accounting Standards.
 - iii. There has been no delay in transferring the amounts, required to



be transferred, to the Investor Education and Protection Fund by the Company.

iv.

(a) The Management has represented that, to the best of its knowledge and belief, no funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the Company to or in any other persons or entities, including foreign entities ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever ("Ultimate Beneficiaries") by or on behalf of the Company or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.

(b) The Management has represented that, to the best of its knowledge and belief, no funds have been received by the Company from any persons or entities, including foreign entities ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the Company shall directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever ("Ultimate Beneficiaries") by or on behalf of the Funding Parties or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.

(c) Based on the audits procedures performed that have been considered reasonable and appropriate in the circumstances, nothing has come to our notice that has caused us to believe that the representations under subclause (i) and (ii) of Rule 11(e) contain any material misstatement.

v) The Company has not declared or paid any dividend during year and hence no compliance is required with Section 123 of the Companies Act, 2013.



KUMBHAT & CO

Chartered Accountants

- vi) ***Based on our examination, which includes test check basis, the accounting software of the Company does not have a feature of recording audit trail (edit log) facility.***

For KUMBHAT & CO.
Chartered Accountants
Firm Regn. No. 001609S



Place: Mumbai
Date: August 27, 2024

A handwritten signature in blue ink, appearing to read "Gaurang C. Unadkat".

Gaurang C. Unadkat
Partner
Mem.No. 131708

UDIN: 24131708BKGIGO1630

Annexure "A" to the Independent Auditor's Report

(Referred to in Paragraph 1 under the heading of "Report on Other Legal and Regulatory Requirements" of our report of even date)

- (i) In respect of the Company's Property, Plant and Equipment and Intangible Assets:
- a) (A) The Company has maintained proper records showing full particulars including quantitative details and situation of fixed assets.
 - (B) The Company has maintained proper records showing full particulars of its intangible assets.
 - b) According to the information and explanation given to us and on the basis of our examination of the records of the Company, the Property, Plant and Equipment have been physically verified by the management in accordance with the phased programme of verification, which, in our opinion, is reasonable having regard to the size of the Company and the nature of its assets. According to information and explanation given to us, no material discrepancies were noticed on such verification.
 - c) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the title deeds of immovable properties (other than immovable properties where the Company is a lessee, and the lease agreements are duly executed in favour of the lessee) are held in the name of the Company.
 - d) According to the information and explanations given to us and on the basis of our examination of the record of the Company, the Company has not revalued its Property, Plant and Equipment (including right of use asset) or intangible assets or both during the year.
 - e) According to the Information and explanation given to us and on the basis of our examination of the records of the Company, no proceedings initiated or pending against the Company for holding any benami property under the Benami Transactions (Prohibition) Act, 1988(as amended in 2016) and rules made thereunder.
- (ii)
- a) As explained to us, the physical verification of inventory has been conducted by the Management in accordance with the phased programme of verification which, In our opinion, is reasonable and no



material discrepancies were noticed on such verification and the discrepancies noticed on physical verification for each class of inventory have been properly dealt with in the books of accounts.

- b) The Company has not been sanctioned working capital limits in excess of Rs. 5 Crore, in aggregate, at any point of time during the year from Banks or Financial Institutions on the basis of security of Current Assets. Hence, Clause 3 (ii)(b) of the order is not applicable.
- (iii) According to the information and explanations given to us, during the year, the Company has neither made any investments in, companies, firms, Limited Liability Partnerships, and nor granted unsecured loans to other parties. Further, the Company has not provided any guarantee or security or granted any advances in the nature of loans, secured or unsecured, to companies, firms, Limited Liability Partnerships or any other parties. Hence reporting under clause 3(iii), (iii)(a), (iii)(b), (iii)(c), (iii)(d), (iii)(e) and (iii)(f) of the Order are not applicable.
- (iv) According to the information and explanations given to us, the Company has not granted any loans, made investment or provided guarantee. Hence, reporting under Clause 3(iv) of the Order is not applicable.
- (v) According to the information and explanation given to us and on the basis of our examination of the records of the company, the Company has not accepted any deposits or amounts which are deemed to be deposits during the year as per the directives issued by the Reserve Bank of India and within the meaning of the provisions of section 73 to 76 and other relevant provisions of the Companies Act, 2013 and the rules framed there under, where applicable. Thus, the Clause (v) of paragraph 3 of the order is not applicable to the company.
- (vi) The Cost records prescribed under Section 148(1) of the Act are not applicable to the Company and hence Clause 3(vi) of the Order is not applicable.
- (vii)
- a. According to the information and explanations given to us and the records of the Company examined by us, in our opinion, the Company is generally been regular in depositing undisputed statutory dues including Goods and Service Tax, Provident Fund, Employees' State Insurance, Income Tax, Goods and Services tax, Custom duty, and other statutory dues as applicable with the appropriate authorities.



There were no undisputed amounts payable in respect of Provident Fund, Employees' State Insurance, Income tax, Goods and Services tax, Customs Duty and other material statutory dues in arrears as at March 31, 2024 for a period of more than six months from the date they become payable.

- (b) There were no dues referred to in sub clause (a) which has not been deposited in on account of any dispute.
- (viii) According to the information and explanation given to us, and on the basis of our examination of the records of the company, there are no such instances noticed where transactions are not recorded in the books of account have been surrendered or disclosed as income during the year in tax assessments under the Income Tax Act, 1961(43 of 1961). There is no previously unrecorded income which was required to be properly recorded in the books of account during the year.
- (ix) In our opinion and according to information and explanation given to us, the Company has not defaulted in repayment of its loans and borrowings to financial institutions, bank, government or dues to debentures holders.
- (x) (a) In our opinion and according to information and explanation given to us, the Company has not raised any moneys by way of Public Offer or further public offer (including debt instruments) during the year. Accordingly, Clause 3(x)(a) of the Order is not applicable.
- (b) During the year, the Company has not made any preferential allotment or private placement of shares or convertible debentures (fully or partly or optionally) and hence reporting under clause 3(x)(b) of the Order is not applicable.
- (xi) (a) Based on the examination of the books and records of the Company and according to the information and explanation given to us, considering the principal of materiality outlined in the Standard on Auditing, we report that no fraud by the Company or on the Company has been noticed or reported during the course of audit.
- (b) According to the information and explanations given to us, no Report under sub-Section 12 of Section 143 of the Act has been filed by the Auditor's in Form ADT-4 as prescribed under Rule 13 of Companies (Audit and Auditors) Rules 2014, with the Central Government.



- (c) According to the information and explanations given to us, no whistle blower complaint has been received by the Company during the year.
- (xii) As the Company is not Nidhi Company, the reporting under clause 3(xii) of the Order is not applicable.
- (xiii) In our opinion and according to the information and explanations given to us the Company is in compliance with Section 177 and 188 of the Companies Act, 2013, where applicable, for all transactions with the related parties and the details of related party transactions have been disclosed in the financial statements etc. as required by the applicable accounting standards.
- (xiv) In our opinion and based on our examination, the company does not satisfy the condition for applicability of Section 138 for conducting internal audit system and hence internal audit has not been conducted.
- (xv) In our opinion and according to the information and explanations given to us, during the period the Company has not entered into any non-cash transactions with its directors or persons connected with him and hence provisions of section 192 of the Companies Act, 2013 are not applicable.
- (xvi)
- (a) The Company is not required to be registered u/s 45-IA of Reserve Bank of India Act, 1934. Accordingly, Clause 3(xvi) (a) and (b) of the Order are not applicable.
- (b) The Company is not a Core Investment Company (CIC) as defined in the regulations made by the Reserve Bank of India. Accordingly, Clause 3(xvi)(c) and (d) of the Order are not applicable.
- (xvii) The Company has not incurred cash losses in the financial year and in the immediately preceding financial year.
- (xviii) There has been resignation of the Statutory Auditors of the Company during the year. There were no issues, objections or concerns raised by the outgoing auditors.
- (xix) According to the information and explanations given to us and on the basis of the financial ratios, ageing and expected dates of realisation of financial assets and payment of financial liabilities, other information

accompanying the standalone financial statements, our knowledge of the Board of Directors and management plans and based on our examination of the evidence supporting the assumptions, nothing has come to our attention, which causes us to believe that any material uncertainty exists as on the date of the audit report that the Company is not capable of meeting its liabilities existing at the date of balance sheet as and when they fall due within a period of one year from the balance sheet date. We, however, state that this is not an assurance as to the future viability of the Company. We further state that our reporting is based on the facts up to the date of the audit report and we neither give any guarantee nor any assurance that all liabilities falling due within a period of one year from the balance sheet date, will get discharged by the Company as and when they fall due.

- (xx) Currently Provisions of Section 135(5) of the Companies Act, relating to Corporate Social Responsibility spending, are not applicable to the Company; hence the reporting under clause 3(xx) of the Order is not applicable.
- (xxi) The Company has no Subsidiaries, Associates and Joint Venture Companies. The Company need not prepare consolidated financial statements and hence the financial statements have been prepared by the management of the company and audited by us on standalone basis. Considering this, the question of qualification or adverse remarks of the respective auditors in the Companies (Auditors' Report) Order (CARO) reports of the companies being included in consolidated financial statement does not arise.

For KUMBHAT & CO.
Chartered Accountants
Firm Regn. No. 001609S



A handwritten signature in blue ink, appearing to read 'Gaurang C. Unadkat'.

Gaurang C. Unadkat
Partner

Mem.No. 131708

Place: Mumbai

Date: August 27, 2024

UDIN: 24131708BKGIGO1630

Annexure "B" to the Independent Auditor's Report

(Referred to in Paragraph 2(f) under the heading of "Report on Other Legal and Regulatory Requirements" of our report of even date)

Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 ("the Act")

We have audited the internal financial controls over financial reporting of **Gujarat Kidney and Superspeciality Limited** ("the Company") as of March 31, 2024 in conjunction with our audit of the financial statements of the Company for the period ended on that date.

Management's Responsibility for Internal Financial Controls

The Company's management is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls over Financial Reporting issued by the Institute of Chartered Accountants of India. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

Auditors' Responsibility

Our responsibility is to express an opinion on the Company's internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls over Financial Reporting (the "Guidance Note") and the Standards on Auditing, to the extent applicable to an audit of internal financial controls, both issued by the Institute of Chartered Accountants of India. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.



Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls system over financial reporting.

Meaning of Internal Financial Controls over Financial Reporting

A company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorisations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Inherent Limitations of Internal Financial Controls over Financial Reporting

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

In our opinion, to the best of information and explanations given to us, the Company has, in all materials respects, an adequate internal financial controls system over financial reporting and such financial controls over financial reporting are operating effectively as at March 31, 2024 based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.

For KUMBHAT & CO.
Chartered Accountants
Firm Regn. No. 001609S



Place: Mumbai

Dated: August 27, 2024

A handwritten signature in blue ink, appearing to read "Gaurang C. Unadkat".

Gaurang C. Unadkat
Partner

Membership No. 131708

UDIN: **24131708BKGIGO1630**

GUJARAT KIDNEY AND SUPERSPECIALITY LIMITED

(CIN : U85300GJ2019PLC111559)

Balance Sheet as at March 31, 2024

(₹. in Lakhs)


	Particulars	Note No.	As at March 31, 2024	As at March 31, 2023
A	<u>EQUITY AND LIABILITIES</u>			
1	<u>Shareholders' funds</u>			
	(a) Share capital	2	20.00	20.00
	(b) Reserves and surplus	3	162.83	17.47
			182.83	37.47
2	<u>Share application money pending for allotment</u>		906.37	-
3	<u>Non-current liabilities</u>			
	(a) Long term borrowings	4	153.04	-
	(b) Long Term Provisions	5	25.51	-
			178.54	-
4	<u>Current liabilities</u>			
	(a) Short term borrowings	6	41.35	-
	(b) Trade payables	7		
	(i) Due to Micro & Small Enterprises		2.77	-
	(ii) Others		237.14	346.75
	(c) Other current liabilities	8	64.46	-
	(d) Short Term Provisions	9	68.46	2.94
			414.18	349.69
			1681.92	387.16
B	<u>ASSETS</u>			
1	<u>Non-current assets</u>			
	(a) Property, Plants and Equipment			
	(i) Tangible Assets	10	973.84	267.18
	(b) Deferred tax Assets (net)	11	9.03	4.04
	(c) Long term loans and advances	12	18.00	-
			1000.87	271.22
2	<u>Non-current Investments</u>	13	0.45	0.59
3	<u>Current assets</u>			
	(a) Inventories	14	27.00	-
	(b) Trade receivables	15	415.75	114.99
	(c) Cash and cash equivalents	16	117.50	0.35
	(d) Other Current Asset	17	120.35	-
			680.61	115.35
			1681.92	387.16
	Significant Accounting Policies	1		
	Notes on financial statement	2-33		

As per our report of even date attached

For Kumbhat & Co.
Chartered Accountants
FRN: 001609S


Gaurang C. Unadkat
Partner
Membership No. 131708
UDIN: 24131708BK4IG01630

For and on behalf of the Board of Directors
Gujarat Kidney and Superspeciality Limited


Pragnesh Yashwantsingh
Bharpoda
Director
DIN: 1033141


Bhartiben Pragnesh
Bharpoda
Director
DIN: 08644746


Bhavikaben Mitesh
Patel
Chief Financial Officer


Veenus Gehlot
Company Secretary

Place : Vadodara
Date : 27/08/2024

Place : Vadodara
Date : 27/08/2024



GUJARAT KIDNEY AND SUPERSPECIALITY LIMITED

(CIN : U85300GJ2019PLC111559)

Statement of Profit and Loss for the year ended March 31, 2024

(₹. in Lakhs)

	Particulars	Note No.	For the year ended March 31, 2024	For the year ended March 31, 2023
1	Revenue From Operations	18	497.97	-
2	Other Income	19	70.35	0.01
3	Total Revenue		568.31	0.01
4	Expenses:			
	Purchase of Stock in Trade	20	57.70	-
	Increase/(Decrease) in Inventories	21	-27.00	-
	Direct Expenses	22	94.88	-
	Employee Benefits Expenses	23	107.29	-
	Finance Costs	24	3.97	-
	Depreciation and amortization Expenses	10	28.25	-
	Other Expenses	25	108.98	0.63
5	Total Expenses		374.06	0.63
6	Profit Before Tax (3-5)		194.25	-0.62
7	Tax Expense			
	Current Tax		53.88	-
	Deferred Tax		4.99	-
	Profit (Loss) after tax for the year		145.36	-0.62
8	Balance Carried Over to Balance Sheet		145.36	-0.62
9	Earning Per Equity Share	30		
	(1) Basic		72.68	(0.31)
	(2) Diluted		72.68	(0.31)
	Significant Accounting Policies	1		
	Notes on financial statement	2-33		


As per our report of even date attached

For Kumbhat & Co.
Chartered Accountants
FRN: 001609S


Gaurang C. Unadkat
Partner
Membership No.131708
UDIN:24131709BK61601630



For and on behalf of the Board of Directors
Gujarat Kidney and Superspeciality Limited


Pragnesh Yashwantsingh Bharpoda
Director
DIN: 1033141


Bhartiben Pragnesh Bharpoda
Director
DIN:08644746


Bhavikaben Mitesh Patel
Chief Financial Officer


Veenus Gehlot
Company Secretary

Place :Vadodara
Date : 27/08/2024

Place :Vadodara
Date : 27/08/2024



GUJARAT KIDNEY AND SUPERSPECIALITY LIMITED

(CIN : U85300GJ2019PLC111559)

Cash flow statement for the period ended 31st March 2024

(₹. in Lakhs)

Particulars	31.03.2024	31.03.2023
Cash flow from operating activities		
Profit/(loss) before tax	194.25	-0.62
Non-cash adjustments to reconcile profit before tax to net cash flows		
Depreciation	28.25	-
Finance Cost	3.97	-
Operating profit/(loss) before working capital changes	226.47	-0.62
Movements in working capital:		
Increase/(decrease) in short term borrowings	41.35	-
Increase/(decrease) in trade payables	-106.84	-5.44
Increase/(decrease) in other current liabilities	64.46	-
Increase/(decrease) in short term provision	65.52	-
Decrease/(increase) in inventories	-27.00	-
Decrease/(increase) in trade receivables	-300.76	6.08
Decrease/(increase) in Other Current Assets	-120.35	-
Cash generated from Operations	-157.16	0.02
Direct taxes paid	-53.88	-
Net Cash from Operating Activities (A)	-211.04	0.02
Cash flows from investing activities		
Sale/(Purchase) of Fixed Assets	-734.91	-
Increase/(decrease) in Non current Investment	0.15	0.00
Net cash flow from/(used in) investing activities (B)	-734.76	-
Cash flow from financing activities		
Acceptance / Repayment of Loans	153.04	-
Finance Cost	-3.97	-
Share Capital Introduced	906.37	-
Increase/(decrease) in Long Term Provisions	25.51	-
Decrease/(increase) in long-term loans and advances	-18.00	-
Net cash flow from/(used in) financing activities (C)	1062.95	-
Net increase/(decrease) in cash and cash equivalents (A+B+C)	117.14	0.02
Cash and cash equivalents at the beginning of the year	0.35	0.34
Cash and cash equivalents at the end of the year	117.50	0.35

As per our report of even date attached

For Kumbhat & Co.
Chartered Accountants
FRN: 001609S

Gaurang C. Unadkat

Gaurang C. Unadkat

Partner

Membership No.131708

UDIN: 24131708BKU1U01630



For and on behalf of the Board of Directors
Gujarat Kidney and Superspeciality Limited

Pragnesh Yashwantsingh Bharpoda

Pragnesh Yashwantsingh Bharpoda

Director

DIN: 1033141

Bhavikaben Mitesh Patel

Bhavikaben Mitesh Patel

Chief Financial Officer

Bhartiben Pragnesh Bharpoda

Bhartiben Pragnesh Bharpoda

Director

DIN:08644746

Veenus Gehlot

Company Secretary

Place :Vadodara

Date :27/08/2024

Place :Vadodara

Date : 27/08/2024



GUJARAT KIDNEY AND SUPERSPECIALITY LIMITED
(CIN : U85300GJ2019PLC111559)

Note 1: Significant Accounting Policies

1. Nature of Business :

- a. M/s GUJARAT KIDNEY AND SUPERSPECIALITY LIMITED (Company) incorporated on December 20, 2019 having CIN: U85300GJ2019PTC111559.
- b. M/s GUJARAT KIDNEY AND SUPERSPECIALITY LIMITED is running a Multi Speciality Hospitals.
- c. The company is compiling all the business & trade practice, and all applicable rule, as notified by appropriate authority, time to time.
- d. The Company has taken over the running business of Gujarat Kidney & Superspeciality Hospital vide Business Transfer Agreement ("BTA") dated February 18, 2024 and transferred the net assets and liabilities of Rs 9,06,36,561 to the Gujarat Kidney and Superspeciality Limited as per the BTA.

2. Basis of Accounting:

- a. The financial statements are prepared under the historical cost convention, in accordance with applicable accounting standards specified under Section 133 of the Companies Act, 2013, read with Rule 7 of the Companies (Accounts) Rules, 2014 and the relevant provision of the Companies Act, 2013.
- b. The accounts have been prepared on a going concern basis under historical cost convention.
- c. Accounting policies not specifically referred to otherwise are in consonance with generally accepted accounting principles followed by the Company.

3. Use of estimates:

The preparation of financial statements in conformity with Generally Accepted Accounting Principles requires estimates and assumptions to be made that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities on the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates and differences between actual results and estimates are recognised in the periods in which the results are known / materialise.

4. Property, Plant and Equipment:

- a. Fixed assets are carried at cost of acquisition less accumulated depreciation.
- b. The cost of fixed assets comprises the purchase price (net of rebates and discounts) and any other directly attributable costs of bringing the assets to their working condition for their intended use.

5. Depreciation:

- a. Depreciation on fixed assets is being provided on Written down value Method as per the useful life prescribed in Schedule II of the Companies Act, 2013.
- b. Depreciation in respect of addition to fixed assets is provided on pro-rata basis from month to month in which such assets acquired/installed.
- c. Depreciation on fixed assets sold, discarded or demolished during the year is being provided at their respective rate upto the month in which such assets are sold, discarded or demolished.

6. Taxation:

- a. Current tax:
Provision for current tax is made on the estimated taxable income at the rate applicable to the relevant assessment year.
- b. Deferred tax:
Deferred tax charge or benefit reflects the tax effects of timing differences between accounting income and taxable income, which originate during the year but reverse in subsequent years.
The deferred tax charge or credit and the corresponding deferred tax liabilities or assets are recognised using the tax rates that have been enacted or substantially enacted by the balance sheet date.

7. Revenue Recognition:

- a. Revenue from hospital services to patients is recognized as revenue when the related services are rendered. Revenue is recognized net of discounts and concessions given to the patients.
- b. Sales of pharmacy products are exclusive of GST and are stated net of discounts. Sale of pharmacy products is recognized when risk and rewards of ownership of the products are passed on to the customers, which is generally on dispatch of goods. Returns against sales and price difference are recognized as and when ascertained and are netted from the amount of sales for the year.

8. Inventories:

Inventories are valued at the lower of cost (Generally determined on FIFO basis) and Net realizable value. Cost includes all charges in bringing the goods to the point of sale, including octroi and other levies, transit insurance and receiving charges.

9. Current & Non Current Classification:

All assets and liabilities have been classified as current or non-current as per the Company's normal operating cycle and other criteria set out in the Act. Deferred tax assets and liabilities are classified as non-current assets and non-current liabilities, as the case may be.



GUJARAT KIDNEY AND SUPERSPECIALITY LIMITED
(CIN : U85300GJ2019PLC111559)

10. Provisions and Contingencies

- a. A provision is recognised when there is a present obligation as a result of past events and it is probable that an outflow of resources will be required to settle the obligation, in respect of which a reliable estimate can be made. Provisions are not discounted to its present value and are determined based on management best estimates of the expenditure required to settle the obligation as at the balance sheet date. Provisions are reviewed at each balance sheet date and adjusted to reflect the current best estimate of each such obligation.
- b. A contingent liability is disclosed when there is a possible or present obligation that may, but probably will not require an outflow of resources, unless the possibility of such outflow is remote.
- c. Contingent Assets are neither recognised nor disclosed.

11. Earnings per Share:

Basic earning per share is computed by dividing the net profit after tax attributable to equity shareholders for the year by the weighted average number of equity shares outstanding during the year. Diluted earning per share is computed by dividing the net profit after tax attributable to equity shareholders for the year by the weighted average number of equity shares outstanding during the year as adjusted for the effects of all dilutive potential equity shares, if any.

12. Leases :

Company as a lessee

Assets acquired on leases wherein a significant portion of the risk and reward of the ownership are retained by the lessor and classified as operating leases. Lease rentals paid for such are recognised as an expense on systematic basis over the term of lease.

13. Cash Flow Statement :

The Cash Flow Statement is prepared by the indirect method set out in Accounting Standard 3 on Cash Flow Statements and presents the cash flows by operating, investing and financing activities of the Company.

Cash and Cash equivalents presented in the Cash Flow Statement consist of cash on hand and unencumbered bank balances and Fixed Deposit with the banks which are short term.



GUJARAT KIDNEY AND SUPERSPECIALITY LIMITED

(CIN : U85300GJ2019PLC111559)

Notes On Financial Statements For The Year Ended 31st March, 2024

(₹. in Lakhs)

Note No.	Particulars	As at March 31, 2024		As at March 31, 2023	
2	Share Capital				
	Authorised Share Capital				
	3,80,00,000 Equity Shares of Rs.10 each		380.00		2.50
	(2,50,00,000 Equity Shares of Rs.10 each)		380.00		2.50
	Issued, Subscribed and Paid up				
	2,00,00,000 Equity Shares of Rs.10each		20.00		20.00
			20.00		20.00
i)	No. of shares Outstanding at the beginning & at the end of the reporting period				
	Particulars	As at March 31, 2024		As at March 31, 2023	
		No.	Rs.	No.	Rs.
	At the beginning of the year	2,00,000	20.00	2,00,000	20.00
	Add: Equity Shares issued during the year	-	-	-	-
	Add: Bonus Shares issued during the year	-	-	-	-
		2,00,000	20,00,000	2,00,000	20,00,000
ii)	Details of Shares held by Promoters /Shareholders holding more than 5% of the aggregate shares in the Company				
		As at March 31, 2024		As at March 31, 2023	
	Name of the Shareholders	No. of Shares held	% of holding	No. of Shares held	% of holding
	Anitaben Y Bharpoda	50,000	25.00%	50,000	25.00%
	Bhartiben P Bharpoda	49,997	25.00%	50,000	25.00%
	Pragnesh Y Bharpoda	50,000	25.00%	50,000	25.00%
	Yashwantsingh Bharpoda	50,000	25.00%	50,000	25.00%
	Total	1,99,997	100.00%	2,00,000	100.00%
iii)	Terms/Rights to Equity Shares				
	(a) The company has only one class of shares i.e. Equity Share				
	(b) All equity shares rank pari-pasu and carry equal right respect to voting and dividend. In the event of liquidation of the company the equity shares				
	(c) All the Equity Shares are having one vote per share				
	(d) All the above Shareholders are also promoters of the company				
	Particulars	As at March 31, 2024		As at March 31, 2023	
3	Reserves and Surplus				
i)	Surplus/(Deficit) in Statement of Profit & Loss				
	Opening Balance		17.47		18.09
	Add: profit/(Loss) during the year		145.36		-0.62
			162.83		17.47
			162.83		17.47



GUJARAT KIDNEY AND SUPERSPECIALITY LIMITED
(CIN : U85300GJ2019PLC111559)
Notes On Financial Statements For The Year Ended 31st March, 2024

(₹ . in Lakhs)

Note No.	Particulars	As at March 31, 2024	As at March 31, 2023																																																																								
4	Long Term Borrowings :																																																																										
	<u>Secured</u>																																																																										
	From bank																																																																										
	- HDFC	33.36	-																																																																								
	[Secured against the Property, plant and equipment - Intuis Intervantional X Ray System]																																																																										
	- Kotak	119.68	-																																																																								
	[Secured against the Property, plant and equipment - Cathlab Equipment]																																																																										
		153.04	-																																																																								
5	Long Term Provisions																																																																										
	Gratuity payable	25.51	-																																																																								
		25.51	-																																																																								
6	Short Term borrowings																																																																										
	<u>Secured</u>																																																																										
	From bank																																																																										
	- HDFC	24.31	-																																																																								
	[Secured against the Property, plant and equipment - Intuis Intervantional X Ray System]																																																																										
	- Kotak	17.04	-																																																																								
	[Secured against the Property, plant and equipment - Cathlab Equipment]																																																																										
		41.35	-																																																																								
7	Trade Payables																																																																										
	Dues to MSME	2.77	-																																																																								
	Other Payable	237.14	346.75																																																																								
		239.91	346.75																																																																								
<table><tr><th>31.03.2023</th><th colspan="5">Outstanding for following periods from due date of payment</th></tr><tr><th>Particulars</th><th>Less than 1 year</th><th>1 to 2 years</th><th>2 to 3 years</th><th>More than 3 years</th><th>Total</th></tr><tr><td>MSME</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td></tr><tr><td>Others</td><td>0.06</td><td>4.40</td><td>342.30</td><td>-</td><td>346.75</td></tr><tr><td>Disputed dues- MSME</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td></tr><tr><td>Disputed dues- Others</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td></tr></table> <table><tr><th>31.03.2024</th><th colspan="5">Outstanding for following periods from due date of payment</th></tr><tr><th>Particulars</th><th>Less than 1 year</th><th>1 to 2 years</th><th>2 to 3 years</th><th>More than 3 years</th><th>Total</th></tr><tr><td>MSME</td><td>2.77</td><td>-</td><td>-</td><td>-</td><td>2.77</td></tr><tr><td>Others</td><td>203.95</td><td>23.81</td><td>4.43</td><td>4.95</td><td>237.14</td></tr><tr><td>Disputed dues- MSME</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td></tr><tr><td>Disputed dues- Others</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td></tr></table>				31.03.2023	Outstanding for following periods from due date of payment					Particulars	Less than 1 year	1 to 2 years	2 to 3 years	More than 3 years	Total	MSME	-	-	-	-	-	Others	0.06	4.40	342.30	-	346.75	Disputed dues- MSME	-	-	-	-	-	Disputed dues- Others	-	-	-	-	-	31.03.2024	Outstanding for following periods from due date of payment					Particulars	Less than 1 year	1 to 2 years	2 to 3 years	More than 3 years	Total	MSME	2.77	-	-	-	2.77	Others	203.95	23.81	4.43	4.95	237.14	Disputed dues- MSME	-	-	-	-	-	Disputed dues- Others	-	-	-	-	-
31.03.2023	Outstanding for following periods from due date of payment																																																																										
Particulars	Less than 1 year	1 to 2 years	2 to 3 years	More than 3 years	Total																																																																						
MSME	-	-	-	-	-																																																																						
Others	0.06	4.40	342.30	-	346.75																																																																						
Disputed dues- MSME	-	-	-	-	-																																																																						
Disputed dues- Others	-	-	-	-	-																																																																						
31.03.2024	Outstanding for following periods from due date of payment																																																																										
Particulars	Less than 1 year	1 to 2 years	2 to 3 years	More than 3 years	Total																																																																						
MSME	2.77	-	-	-	2.77																																																																						
Others	203.95	23.81	4.43	4.95	237.14																																																																						
Disputed dues- MSME	-	-	-	-	-																																																																						
Disputed dues- Others	-	-	-	-	-																																																																						
8	Other Current Liabilities																																																																										
	Statutory Dues	34.01	-																																																																								
	Salary Payable	30.46	-																																																																								
		64.46	-																																																																								
9	Short Term Provisions																																																																										
	Provision for Expenses	12.32	2.94																																																																								
	Gratuity payable	2.26	-																																																																								
	Provision For Income Tax (Net-off)	53.88	-																																																																								
		68.46	2.94																																																																								



Notes On Financial Statements For The Year Ended 31st March, 2024
Depreciation as per Companies Act

Note No :- 10		(₹. in Lakhs)									
Particulars	GROSS BLOCK				DEPRECIATION BLOCK				NET BLOCK		
	As on 01/04/2023	Addition during the period	Deductions during the period	As at 31/03/2024	Total up to 01/04/2024	Deduction/ Adjustment during the year	Provided for the year	Total up to 31/03/2024	Total as on 31/03/2024	Total as on 31/03/2023	
Building	-	122.33	-	122.33	-	-	0.61	0.61	121.72	-	
Plant & Machinery	267.18	718.50	267.18	718.50	-	-	19.14	19.14	699.36	267.18	
Office Equipments	-	32.82	-	32.82	-	-	0.95	0.95	31.87	-	
Computer	-	0.00	-	-	-	-	0.31	0.31	1.24	-	
Furniture & Fixtures	-	114.72	-	114.72	-	-	6.49	6.49	108.22	-	
Motor Vehicle	-	0.00	-	-	-	-	0.74	0.74	11.44	-	
	-	12.18	-	-	-	-	-	-	-	-	
TOTAL	267.18	1002.09	267.18	1002.09	-	-	28.25	28.25	973.84	267.18	
Previous Year	267.18	-	-	267.18	-	-	-	-	267.18	-	



GUJARAT KIDNEY AND SUPERSPECIALITY LIMITED
(CIN : U85300GJ2019PLC111559)
Notes On Financial Statements For The Year Ended 31st March, 2024

(₹ . in Lakhs)

Note No.	Particulars	As at March 31, 2024	As at March 31, 2023																																																																																				
11	Net Deferred Tax Assets																																																																																						
	Deferred Tax Asset	9.03	4.04																																																																																				
		9.03	4.04																																																																																				
12	Long Term Loans and Advances (Unsecured, considered good unless otherwise stated)																																																																																						
	Security Deposits	18.00	-																																																																																				
		18.00	-																																																																																				
13	Non-current Investments																																																																																						
	Preliminary Expenses	0.45	0.59																																																																																				
		0.45	0.59																																																																																				
14	Inventories																																																																																						
	Stock in Hand	27.00	-																																																																																				
		27.00	-																																																																																				
15	Trade Receivables Unsecured, Considered Good																																																																																						
	Over six months from the due date	122.92	-																																																																																				
	Others	292.83	114.99																																																																																				
		415.75	114.99																																																																																				
<table><tr><th>31.03.2023</th><th colspan="6">Outstanding for following periods from due date of payment</th></tr><tr><th>Particulars</th><th>Less than 6 months</th><th>6 months to 1 year</th><th>1 to 2 years</th><th>2 to 3 years</th><th>More than 3 years</th><th>Total</th></tr><tr><td>Undisputed trade receivables - considered good</td><td>-</td><td>-</td><td>114.99</td><td>-</td><td>-</td><td>114.99</td></tr><tr><td>Undisputed trade receivables - credit impaired</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td></tr><tr><td>Disputed trade receivables - considered good</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td></tr><tr><td>Disputed trade receivables - credit impaired</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td></tr></table> <table><tr><th>31.03.2024</th><th colspan="6">Outstanding for following periods from due date of payment</th></tr><tr><th>Particulars</th><th>Less than 6 months</th><th>6 months to 1 year</th><th>1 to 2 years</th><th>2 to 3 years</th><th>More than 3 years</th><th>Total</th></tr><tr><td>Undisputed trade receivables - considered good</td><td>292.83</td><td>60.03</td><td>57.35</td><td>5.54</td><td>-</td><td>415.75</td></tr><tr><td>Undisputed trade receivables - credit impaired</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td></tr><tr><td>Disputed trade receivables - considered good</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td></tr><tr><td>Disputed trade receivables - credit impaired</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td></tr></table>				31.03.2023	Outstanding for following periods from due date of payment						Particulars	Less than 6 months	6 months to 1 year	1 to 2 years	2 to 3 years	More than 3 years	Total	Undisputed trade receivables - considered good	-	-	114.99	-	-	114.99	Undisputed trade receivables - credit impaired	-	-	-	-	-	-	Disputed trade receivables - considered good	-	-	-	-	-	-	Disputed trade receivables - credit impaired	-	-	-	-	-	-	31.03.2024	Outstanding for following periods from due date of payment						Particulars	Less than 6 months	6 months to 1 year	1 to 2 years	2 to 3 years	More than 3 years	Total	Undisputed trade receivables - considered good	292.83	60.03	57.35	5.54	-	415.75	Undisputed trade receivables - credit impaired	-	-	-	-	-	-	Disputed trade receivables - considered good	-	-	-	-	-	-	Disputed trade receivables - credit impaired	-	-	-	-	-	-
31.03.2023	Outstanding for following periods from due date of payment																																																																																						
Particulars	Less than 6 months	6 months to 1 year	1 to 2 years	2 to 3 years	More than 3 years	Total																																																																																	
Undisputed trade receivables - considered good	-	-	114.99	-	-	114.99																																																																																	
Undisputed trade receivables - credit impaired	-	-	-	-	-	-																																																																																	
Disputed trade receivables - considered good	-	-	-	-	-	-																																																																																	
Disputed trade receivables - credit impaired	-	-	-	-	-	-																																																																																	
31.03.2024	Outstanding for following periods from due date of payment																																																																																						
Particulars	Less than 6 months	6 months to 1 year	1 to 2 years	2 to 3 years	More than 3 years	Total																																																																																	
Undisputed trade receivables - considered good	292.83	60.03	57.35	5.54	-	415.75																																																																																	
Undisputed trade receivables - credit impaired	-	-	-	-	-	-																																																																																	
Disputed trade receivables - considered good	-	-	-	-	-	-																																																																																	
Disputed trade receivables - credit impaired	-	-	-	-	-	-																																																																																	
16	Cash And Cash Equivalents																																																																																						
	Cash On Hand	18.90	-																																																																																				
	Balance With Bank																																																																																						
	-On Current Account	78.14	0.35																																																																																				
	-On Fixed Deposit Account	20.46	-																																																																																				
		117.50	0.35																																																																																				
17	Other Current Asset																																																																																						
	Advance given to Creditors	12.83	-																																																																																				
	Balances with Revenue Authorities	17.44	-																																																																																				
	Accrued Interest on Fixed Deposit	0.18	-																																																																																				
	Prepaid Expenses	7.12	-																																																																																				
	IPO Expenses	22.52	-																																																																																				
	Other Advances	60.26	-																																																																																				
		120.35	-																																																																																				



GUJARAT KIDNEY AND SUPERSPECIALITY LIMITED

(CIN : U85300GJ2019PLC111559)

Notes to and forming part of statement of Profit and Loss for the year ended March 31, 2024

(₹. in Lakhs)

Note No.	Particulars	For the year ended 31st March, 2024	For the year ended 31st March, 2023
18	<u>Revenue From Operations</u>		
	Sale of Services	412.97	-
	Sale of Goods	85.00	-
		497.97	-
19	<u>Indirect Incomes</u>		
	Interest on Fixed Deposit	0.18	-
	Interest on Income Tax Refund	-	0.01
	Profit on sale of Fixed Assets	70.16	-
		70.35	0.01
20	<u>Purchase of Stock in Trade</u>		
	Purchases	57.70	-
		57.70	-
21	<u>(Increase)/Decrease in Inventories</u>		
	Inventories at the end of the year	27.00	-
	Inventories at the beginning of the year	-	-
		-27.00	-
22	<u>Direct Expenses</u>		
	Catering Expenses	1.57	-
	Drugs & Medicine Expenses	2.59	-
	Professional fees	75.23	-
	Hospital Consumption Charges	4.20	-
	Lab Testing Fees Exp.	9.53	-
	Laundry Exp	0.57	-
	Medical Oxygen Gas Exp.	1.19	-
		94.88	-
23	<u>Employee Benefits Expense</u>		
	Salary Expenses	70.93	-
	Directors Remuneration	22.76	-
	Staff Welfare Expenses	1.02	-
	Employer's Contribution to P.F.	4.23	-
	Gratuity Expenses	8.34	-
		107.29	-



GUJARAT KIDNEY AND SUPERSPECIALITY LIMITED

(CIN : U85300GJ2019PLC111559)

Notes to and forming part of statement of Profit and Loss for the year ended March 31, 2024

(₹. in Lakhs)

Note No.	Particulars	For the year ended 31st March, 2024	For the year ended 31st March, 2023
24	Finance Cost		
	Bank Charges	0.30	-
	Brokerage	0.53	-
	Interest on loans	3.14	-
		3.97	-
25	Other Expenses		
	Advertisement Expenses	5.40	-
	Audit Fees	1.00	0.40
	Business Promotion Exp	0.03	-
	Courier Charges	0.04	-
	Discount	20.53	-
	Electricity Charges	7.92	-
	Miscellaneous Expense	4.12	-
	Petrol Expenses	0.10	-
	Printing & Stationery	2.65	-
	Professional and Consultancy fees	5.91	-
	Rent	5.67	0.23
	Rates and Taxes	48.07	-
	Repairs & Maintenance	5.23	-
	Security Expenses	0.99	-
	Travelling Expenses	1.32	-
		108.98	0.63



GUJARAT KIDNEY AND SUPERSPECIALITY LIMITED**(CIN: U85300GJ2019PLC111559)****26. Related party Disclosers as required by AS 18 of the Institute of Chartered Accountants of India is as follows:**

❖ Directors Of The Company:

1. Mr. Yashwantsingh Bharpoda
2. Mrs. Anitaben Yashvantsinh Bharpoda
3. Mr. Pragnesh Yashvantsinh Bharpoda
4. Mrs. Bhartiben Pragnesh Bharpoda

❖ Key Management Personnel:

- | | |
|--|---------------------------|
| 1. Mr. Yashwantsingh Bharpoda | - Director |
| 2. Mrs. Anitaben Yashvantsinh Bharpoda | - Director |
| 3. Mr. Pragnesh Yashvantsinh Bharpoda | - Director |
| 4. Mrs. Bhartiben Pragnesh Bharpoda | - Director |
| 5. Mrs. Bhavikaben Mitesh Patel | - Chief Financial officer |
| 6. Mr. Veenus Gehlot | - Company Secretary |

❖ Relatives of the Director/s

1. Mrs. Nikitaben Patel sister of Pragnesh Yashvantsinh Bharpoda.

❖ Enterprise over which Key Management Personnel exercise significant influence:

1. Y M Bharpoda HUF
2. Gold Cost Laboratory
3. New Gujarat Pharmacy

❖ Transaction during the year

(₹. in Lakhs)

Type of Related Party	Description of the Nature	Party Name	FY 2023-24			FY 2022-23		
			Opening Balance	Volume of Transactions during the year	Closing Balance	Opening Balance	Volume of Transactions during the year	Closing Balance
Director	Remuneration	Pragnesh Yashwantsingh Bharpoda	-	20.69	-	-	-	-
	Business Transfer Agreement		-	906.37	906.37	-	-	-
	Loan Given		-	210.23	68.51	-	-	-
	Rent		-	2.12	-	-	-	-
Director	Remuneration	Bhartiben Pragnesh Bharpoda (Gold Cost Laboratory)	-	2.07	2.07	-	-	-
	Service		-	110.51	83.01	-	-	-
Director	Purchase	Anita Bharpoda (New Gujarat Pharmacy)	-	27.33	5.33	-	-	-
Director	Loan Taken	Yashwantsingh Bharpoda	-	139.50	-	-	-	-
Chief financial Officer	Salary	Bhavikaben Mitesh Patel	-	0.77	0.39	-	-	-
Relative's	Loan Taken	Y M BHARPODA HUF	-	117.72	-	-	-	-



GUJARAT KIDNEY AND SUPERSPECIALITY LIMITED**(CIN: U85300GJ2019PLC111559)****27. Deferred Taxation:****(₹. in Lakhs)**

	Items of Timing Difference	Accumulated Deferred Tax (Asset) / Liability as on April 1, 2023	Charge/ (credit) for the year	Accumulated Deferred Tax (Asset)/ Liability as on March 31, 2024
Deferred Tax Assets				
I.	Depreciation	(4.04)	(2.89)	(6.93)
Deferred Tax Liabilities				
II	Gratuity		(2.10)	(2.10)
Net Deferred Tax		(4.04)	(4.99)	(9.03)

28. Dues to Micro & Small Enterprises:**(₹. in Lakhs)**

Sr. No.	Particulars	As on 31 st March 2024	As on 31 st March 2023
1	Principal amount due to suppliers registered under the MSMED Act and remaining unpaid as at the end of year.	2.77	-
2	Interest due to suppliers registered under the MSMED Act and remaining unpaid as to at year end.		-
3	Principal amount paid to suppliers registered under MSMED Act, beyond the appointed day during the year.	-	-
4	Interest paid other than under section 16 of MSMED Act, to supplier registered under the MSMED Act beyond the appointed day during the year.	-	-
5	Interest paid, under Section 16 of MSMED Act, to suppliers registered under the MSMED Act, beyond the appointed day during the year.	-	-
6	Interest due and payable towards suppliers registered under MSMED Act, for payments already made.	-	-
7	Further interest remaining due and payable for earlier years.	-	-

On the basis of information and records available with the company, the above disclosures are made in respect of amounts due to the micro and small enterprises, who have registered with the relevant competent authorities



GUJARAT KIDNEY AND SUPERSPECIALITY LIMITED**(CIN: U85300GJ2019PLC111559)****29. Auditors Remunerations:****(₹. in Lakhs)**

Particulars	For the year ended March 31, 2024	For the year ended March 31, 2023
Statutory Audit fees	1.00	0.40
Total	1.00	0.40

30. Earnings per share:**(₹. in Lakhs)**

Particulars	For the period ended on March 31, 2024	For the period ended on March 31, 2023
Profit/(loss) for the Year (Rs.) (A)	145.36	(0.62)
Weighted Average Number of Equity Shares (B)	2,00,000	2,00,000
Earnings per Share – Basic and Diluted (Rs.) (A/B)	72.68	(0.31)
Nominal Value of an Equity Share (Rs.)	10.00	10.00

31. The particulars as required under the Accounting Standard-AS 15 of Employees Benefits are as under:

As Defined Contribution plan:

(₹. in Lakhs)

Particulars	For the year ended March 31, 2024	For the year ended March 31, 2023
Contribution to Employees Provident Fund	3.90	0.00

i. As Defined Benefit Plan

Following are the principle Actuarial Assumptions used for determining defined benefit obligation towards gratuity as of the Balance Sheet Dates.

Particulars	For the year ended March 31, 2024	For the year ended March 31, 2023
Retirement Age	60 years	-
Future Salary Rise	10.00 %	-
Rate of Discount	7.20 %	-
Method Used for Measuring Liabilities	Projected Unit Credit Method	-

Current and Non-Current Liability:

(₹. in Lakhs)

Particulars	For the year ended March 31, 2024	For the year ended March 31, 2023
Funding Status	Unfunded	-
Fund Balance	N.A	-
Current Liability	2.26	-
Non-Current Liability	25.51	-



GUJARAT KIDNEY AND SUPERSPECIALITY LIMITED
(CIN: U85300GJ2019PLC111559)

As per the Actuarial Valuation Report of Gratuity Liability, based on the above assumptions, gratuity liability as on March 31, 2024 works out to INR 27,76,901 /- The same has been provided in the books of accounts.

32. Disclosure of Accounting Ratios and Reasons for Variance

(₹ . in Lakhs)

DISCLOSURE OF ACCOUNTING RATIOS AND REASON FOR VARIANCE						
	Particulars	Formula for Computation	Measures (in times / percentage)	For the Year Ended 31 Mar 2024	For the Year Ended 31 Mar 2023	% Change [2023-2024]
A	Current Ratio	Current assets / Current liabilities	Times	1.64	0.33	398.13%
B	Debt Equity Ratio	Debt / Net worth	Times	1.06	-	N/A
C	Debt Service Coverage Ratio	EBITDAE / (Finance costs + Principal repayment of long term borrowings within one year)	Times	5.48	N/A	N/A
D	Return on Equity	Profit after tax / Net worth	Percentage	13.35%	-1.66%	-904.47%
E	Inventory Turnover Ratio	Cost of goods sold / Average inventory	Times	2.27	-	N/A
F	Trade Receivable Turnover Ratio	[Revenue from Sales of products (including excise duty) + Sales of services] / Average gross trade receivables	Times	1.88	N/A	N/A
G	Trade Payable Turnover Ratio	Purchases / Average trade payables	Times	0.20	N/A	N/A
H	Net Capital Turnover Ratio	Revenue from operations / working capital	Times	1.87	-	N/A
I	Net Profit Ratio	Profit after tax / Revenue from operations	Percentage	29.21%	N/A	N/A
J	Return on Capital Employed (ROCE)	EBIT / Capital employed	Percentage	18.24%	-1.66%	-1198.85%

Notes

- 1 Debt = Non-current borrowings + Current borrowings
- 2 Net worth = Paid-up share capital + Reserves created out of profit+ Security premium - Accumulated losses
- 3 Cost of goods sold = Cost of materials consumed + Purchase of stock-in-trade + Changes in inventories of finished
- 4 Purchase = Purchase of stock-in-trade + Purchase of Raw Material and packing material
- 5 Working Capital = Current assets - Current liabilities
- 6 EBIT = Earnings before Interest, tax and exceptional items
- 7 Capital employed = Total equity + Non-current borrowings

Disclosure of change in ratio by more than 25%		
Particulars	% Variance in ratio between 31 March 2024 and 31 March 2023	Reason for Variance
Current Ratio	398.13%	Due to increase in current assets
Return on Equity	-904.47%	Due to increase in profit after tax and share application
Return on Capital Employed (ROCE)	-1198.85%	money received allotment pending



GUJARAT KIDNEY AND SUPERSPECIALITY LIMITED

(CIN: U85300GJ2019PLC111559)

33. Debtors & Creditors balances are subject to confirmation. Adjustments, if any, will be made in the accounts on the receipt of such confirmations.
34. In the opinion of the Board, current assets, loans and advances have a value on realization at least equal to the amount at which they are stated in the accounts.

As per our attached report of even date

**For Kumbhat & Co.
Chartered Accountants
FRN:001609S**

**Gaurang C. Unadkat
Partner**

Membership No. 131708



Place : Vadodara

Date : 27/09/2024

UDIN: 24131708BH41601630

**For and on behalf of the Board of Directors
Gujarat Kidney and Superspeciality Limited**

**Pragnesh Yashwantsingh
Bharpoda
Director**

DIN: 1033141

**Bhartiben Pragnesh
Bharpoda
Director**

DIN:08644746

**Bhavikaben Mitesh Patel
Chief Financial Officer**

Place : Vadodara

Date : 27/08/2024

**Veenus Gehlot
Company Secretary**

